NCT01634295 - Efficacy and Safety of CKD-828 to Stage 2 Hypertension | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Hypertension

Interventions

DRUG

CKD-828 2.5/40mg

"* Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."

DRUG

CKD-828 5/40mg

"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."

DRUG

CKD-828 5/80mg

"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks."

DRUG

S-amlodipine 2.5mg

"* S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks."

DRUG

S-amlodipine 5mg

"* S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks."

Trial Locations (1)

Seoul national university Bundang Hospital, Bundang-gu